Press release
Frontotemporal Dementia Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Alector, Oncolys BioPharma, Denali Therapeutics Inc, Passage Bio
"Frontotemporal Dementia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Frontotemporal Dementia Market.
The Frontotemporal Dementia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Frontotemporal Dementia Pipeline Report: https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Frontotemporal Dementia treatment therapies with a considerable amount of success over the years.
• Frontotemporal Dementia companies working in the treatment market are Deep Genomics, Asceneuron SA, AviadoBio, CAMP4 Therapeutics, Neurimmune, Prevail Therapeutics, Passage Bio, Transposon Therapeutics, Alector Inc., and others, are developing therapies for the Frontotemporal Dementia treatment
• Emerging Frontotemporal Dementia therapies in the different phases of clinical trials are- Research programme CNS Therapies, Research Program M1 PAM, AVB-101, Research programme CNS, NI308, PR006, PBFT02, TPN-101, AL001, and others are expected to have a significant impact on the Frontotemporal Dementia market in the coming years.
• In December 2023, The Danish biotechnology company, Vesper Bio, has administered the initial dose to the first participant in a Phase I trial assessing the oral medication VES001 for frontotemporal dementia (FTD). This randomized, double-blind trial aims to evaluate the safety and tolerability of Vesper Bio's compound, VES001, which the company describes as a first-of-its-kind brain-penetrating medication.
• In February 2022, The completion of a Series B fundraising for $64 million was announced by Arkuda Therapeutics. Together with Eli Lilly and Company, Surveyor Capital (a Citadel company), and current investors Pfizer Ventures, Tekla Capital Management LLC funds, Mission BioCapital, and Atlas Venture, Cormorant Asset Management and Pivotal bioVenture Partners co-led the financing.
• In January 2022, The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer's Drug Discovery Foundation (ADDF) announced their collaboration to support Wave Life Sciences' FOCUS-C9 Phase 1b/2a clinical trial, which looks into WVE-004 as a possible treatment for amyotrophic lateral sclerosis (C9-ALS) and C9orf72-associated frontotemporal degeneration (C9-FTD).
Frontotemporal Dementia Overview
Frontotemporal dementia (FTD) is a collective term for a set of disorders caused by gradual loss of function in the brain's frontal and temporal lobes. These brain regions are crucial for behavior, language, and decision-making skills.
Get a Free Sample PDF Report to know more about Frontotemporal Dementia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Frontotemporal Dementia Drugs Under Different Phases of Clinical Development Include:
• Research programme CNS Therapies: Deep Genomics
• Research Program M1 PAM: Asceneuron SA
• AVB-101: AviadoBio
• Research programme CNS: CAMP4 Therapeutics
• NI308: Neurimmune
• PR006: Prevail Therapeutics
• PBFT02: Passage Bio
• TPN-101: Transposon Therapeutics
• AL001: Alector Inc.
Frontotemporal Dementia Route of Administration
Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Frontotemporal Dementia Molecule Type
Frontotemporal Dementia Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Frontotemporal Dementia Pipeline Therapeutics Assessment
• Frontotemporal Dementia Assessment by Product Type
• Frontotemporal Dementia By Stage and Product Type
• Frontotemporal Dementia Assessment by Route of Administration
• Frontotemporal Dementia By Stage and Route of Administration
• Frontotemporal Dementia Assessment by Molecule Type
• Frontotemporal Dementia by Stage and Molecule Type
DelveInsight's Frontotemporal Dementia Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Frontotemporal Dementia product details are provided in the report. Download the Frontotemporal Dementia pipeline report to learn more about the emerging Frontotemporal Dementia therapies
https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Frontotemporal Dementia Therapeutics Market include:
Key companies developing therapies for Frontotemporal Dementia are - Alector Inc., Transposon Therapeutics, Oncolys BioPharma, Denali Therapeutics Inc, Passage Bio, Inc., Prevail Therapeutics, Wave Life Sciences, and others.
Frontotemporal Dementia Pipeline Analysis:
The Frontotemporal Dementia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Frontotemporal Dementia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Frontotemporal Dementia Treatment.
• Frontotemporal Dementia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Frontotemporal Dementia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Frontotemporal Dementia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Frontotemporal Dementia drugs and therapies
https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Frontotemporal Dementia Pipeline Market Drivers
• Increasing prevalence of geriatric population, increasing drug development grants, increasing collaborations among companies are some of the important factors that are fueling the Frontotemporal Dementia Market.
Frontotemporal Dementia Pipeline Market Barriers
• However, lack of proper diagnosis, higher chances of misunderstanding with Alzheimer's disease and other factors are creating obstacles in the Frontotemporal Dementia Market growth.
Scope of Frontotemporal Dementia Pipeline Drug Insight
• Coverage: Global
• Key Frontotemporal Dementia Companies: Deep Genomics, Asceneuron SA, AviadoBio, CAMP4 Therapeutics, Neurimmune, Prevail Therapeutics, Passage Bio, Transposon Therapeutics, Alector Inc., and others
• Key Frontotemporal Dementia Therapies: Research programme CNS Therapies, Research Program M1 PAM, AVB-101, Research programme CNS, NI308, PR006, PBFT02, TPN-101, AL001, and others
• Frontotemporal Dementia Therapeutic Assessment: Frontotemporal Dementia current marketed and Frontotemporal Dementia emerging therapies
• Frontotemporal Dementia Market Dynamics: Frontotemporal Dementia market drivers and Frontotemporal Dementia market barriers
Request for Sample PDF Report for Frontotemporal Dementia Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Frontotemporal Dementia Report Introduction
2. Frontotemporal Dementia Executive Summary
3. Frontotemporal Dementia Overview
4. Frontotemporal Dementia- Analytical Perspective In-depth Commercial Assessment
5. Frontotemporal Dementia Pipeline Therapeutics
6. Frontotemporal Dementia Late Stage Products (Phase II/III)
7. Frontotemporal Dementia Mid Stage Products (Phase II)
8. Frontotemporal Dementia Early Stage Products (Phase I)
9. Frontotemporal Dementia Preclinical Stage Products
10. Frontotemporal Dementia Therapeutics Assessment
11. Frontotemporal Dementia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Frontotemporal Dementia Key Companies
14. Frontotemporal Dementia Key Products
15. Frontotemporal Dementia Unmet Needs
16 . Frontotemporal Dementia Market Drivers and Barriers
17. Frontotemporal Dementia Future Perspectives and Conclusion
18. Frontotemporal Dementia Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Frontotemporal Dementia Market https://www.delveinsight.com/report-store/frontotemporal-dementia-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Frontotemporal Dementia Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Frontotemporal Dementia Epidemiology https://www.delveinsight.com/report-store/frontotemporal-dementia-ftd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Frontotemporal Dementia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Frontotemporal Dementia Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Alector, Oncolys BioPharma, Denali Therapeutics Inc, Passage Bio here
News-ID: 3504561 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Frontotemporal
Frontotemporal Dementia (FTD) Market to Reach USD 4.3 Billion by 2034
Frontotemporal Dementia (FTD) is a rare yet serious group of neurodegenerative disorders characterized by progressive damage to the frontal and temporal lobes of the brain. Unlike Alzheimer's disease, FTD often manifests earlier in life, typically between the ages of 40 and 65, and is marked by personality changes, impaired judgment, and language difficulties. Its early onset and challenging diagnosis make it one of the most complex forms of dementia to…
Frontotemporal Dementia Market Set to Double by 2034, Reaching USD 4.2 Billion
The global FTD market was valued at USD 2.1 billion in 2024 and is projected to reach USD 4.2 billion by 2034, growing at a CAGR of 7.1%. Rising diagnosis rates, growing investment in neurodegenerative disease research, and expanded healthcare access are driving this growth.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70788
Key Market Highlights
• Increasing recognition of FTD as distinct from Alzheimer's and other dementias.
• Expanding pipeline of clinical trials…
Frontotemporal Dementia Treatment Market - Empathy in Action: Pioneering Frontot …
Newark, New Castle, USA: The "Frontotemporal Dementia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Frontotemporal Dementia Treatment Market: https://www.growthplusreports.com/report/frontotemporal-dementia-treatment-market/8569
This latest report researches the industry structure,…
Frontotemporal Dementia Treatment Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "Frontotemporal Dementia Treatment Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly studies…
Frontotemporal Disorder Treatment Market Size, Share, Impressive Industry Growth …
The global Frontotemporal Disorder treatment market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising orphan drug development initiatives by the FDA, new product launches and the growing geriatric population are some of the key factors contributing to the growth of the global Frontotemporal Disorder treatment market. According to the World Health Organization, in 2019 around 50 million people are living with dementia and the number…
Improvement In Cognitive Empathy to Drive The Frontotemporal Dementia Treatment …
The global Frontotemporal Dementia Treatment Market is bound to witness a CAGR worth satiating In Upcoming Years. In the era of cloud computing, the cloud revolution is there to break the stereotypes. Several key stakeholders are going for cloud hosting solutions providers to enhance their accounting services. This migration to cloud technology is making way for the enterprises to simplify their daily tasks, that too, conveniently and cost-effectively. As such,…
